Sarepta Therapeutics (NASDAQ:SRPT) Sets New 1-Year Low Following Analyst Downgrade

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report)'s share price hit a new 52-week low during trading on Thursday after Royal Bank of Canada lowered their price target on the stock from $165.00 to $161.00. Royal Bank of Canada currently has an outperform rating on the stock. Sarepta Therapeutics traded as low as $101.00 and last traded at $108.35, with a volume of 150140 shares trading hands. The stock had previously closed at $106.86.

Several other analysts also recently commented on the stock. Piper Sandler reduced their price objective on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating for the company in a research report on Wednesday, November 27th. Robert W. Baird reduced their price target on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an "outperform" rating for the company in a report on Thursday, November 7th. Cantor Fitzgerald upgraded shares of Sarepta Therapeutics from a "neutral" rating to an "overweight" rating and upped their price objective for the company from $152.00 to $167.00 in a report on Thursday, November 7th. Deutsche Bank Aktiengesellschaft started coverage on shares of Sarepta Therapeutics in a research report on Tuesday, February 11th. They set a "hold" rating and a $136.00 price objective on the stock. Finally, Guggenheim boosted their target price on Sarepta Therapeutics from $148.00 to $150.00 and gave the company a "buy" rating in a research report on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $173.52.

Insider Activity

In other news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business's stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the transaction, the director now owns 22,840 shares in the company, valued at $2,851,345.60. The trade was a 31.49 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Kathryn Jean Boor sold 1,636 shares of the stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the sale, the director now directly owns 5,880 shares of the company's stock, valued at $738,234. The trade was a 21.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of SRPT. Vanguard Group Inc. raised its stake in shares of Sarepta Therapeutics by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 9,085,456 shares of the biotechnology company's stock worth $1,104,701,000 after purchasing an additional 117,904 shares during the period. Capital International Investors increased its holdings in Sarepta Therapeutics by 38.9% during the fourth quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company's stock worth $1,057,482,000 after buying an additional 2,437,855 shares during the last quarter. Janus Henderson Group PLC raised its position in Sarepta Therapeutics by 14.2% in the third quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company's stock worth $544,408,000 after acquiring an additional 543,143 shares during the period. Farallon Capital Management LLC boosted its stake in Sarepta Therapeutics by 11.1% in the fourth quarter. Farallon Capital Management LLC now owns 2,865,100 shares of the biotechnology company's stock valued at $348,368,000 after acquiring an additional 285,100 shares during the last quarter. Finally, Wellington Management Group LLP grew its position in shares of Sarepta Therapeutics by 32.3% during the 3rd quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company's stock valued at $340,527,000 after acquiring an additional 665,087 shares during the period. Hedge funds and other institutional investors own 86.68% of the company's stock.

Sarepta Therapeutics Stock Performance

The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The company has a market cap of $9.67 billion, a PE ratio of 80.98 and a beta of 0.75. The company's 50 day moving average price is $115.89 and its 200-day moving average price is $122.46.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.